Why is vyzulta so expensive

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Vyzulta (latanoprostene bunod ophthalmic solution) is expensive primarily due to its patented formulation, which combines latanoprost with nitric oxide-donating molecules to enhance efficacy. Launched in the U.S. in December 2017 by Bausch + Lomb, it costs around $200-$300 per bottle without insurance, compared to $50-$100 for generic latanoprost. The high price reflects research and development costs, clinical trials, and marketing, with patents extending exclusivity until at least 2032. Insurance coverage and patient assistance programs can reduce out-of-pocket expenses.

Key Facts

Vyzulta was FDA-approved in November 2017 and launched in December 2017
It costs approximately $200-$300 per bottle without insurance
Patents protect Vyzulta from generic competition until at least 2032
Vyzulta combines latanoprost with nitric oxide-donating molecules
Clinical trials showed it reduced intraocular pressure by 7-9 mmHg on average

Overview

Vyzulta (latanoprostene bunod ophthalmic solution) is a prescription eye drop used to treat open-angle glaucoma and ocular hypertension by lowering intraocular pressure (IOP). Developed by NicOx and licensed to Bausch + Lomb, it received FDA approval on November 2, 2017, and launched commercially in the United States in December 2017. The medication represents an advancement in prostaglandin analog therapies, building upon the success of latanoprost (marketed as Xalatan since 1996) but with enhanced mechanisms. Glaucoma affects over 3 million Americans, with treatment costs contributing to significant healthcare expenditures. Vyzulta's introduction aimed to provide an alternative for patients who do not respond adequately to existing treatments, with Bausch + Lomb investing heavily in its development and marketing to establish it in a competitive market dominated by generics.

How It Works

Vyzulta works through a dual mechanism of action that combines latanoprost, a prostaglandin analog, with a nitric oxide-donating moiety. Once administered as an eye drop, it is metabolized into two active components: latanoprost acid and butanediol mononitrate. The latanoprost acid increases uveoscleral outflow of aqueous humor by relaxing ciliary muscle and remodeling extracellular matrix, while the nitric oxide donor enhances trabecular meshwork outflow by relaxing smooth muscle and improving drainage through the conventional pathway. This dual action results in a more significant reduction in intraocular pressure compared to latanoprost alone, with clinical studies showing an average IOP reduction of 7-9 mmHg. The medication is typically dosed once daily in the evening, and its efficacy is maintained over long-term use, making it a valuable option for managing glaucoma progression.

Why It Matters

Vyzulta's high cost matters because it impacts accessibility for glaucoma patients, particularly those without adequate insurance, potentially leading to non-adherence and increased risk of vision loss. Glaucoma is a leading cause of irreversible blindness worldwide, affecting over 80 million people globally, with effective IOP control being crucial to prevent optic nerve damage. The expense reflects broader issues in pharmaceutical pricing, where innovation and patent protection drive up prices, but it also underscores the need for cost-effective treatments in chronic diseases. Real-world applications show that Vyzulta can benefit patients who require additional IOP reduction beyond first-line therapies, though its use may be limited by affordability. This highlights the ongoing balance between rewarding innovation and ensuring patient access to essential medications.